keyword
MENU ▼
Read by QxMD icon Read
search

metastatic cancer chemotherapy

keyword
https://www.readbyqxmd.com/read/29161698/a-comparison-of-three-methods-for-the-detection-of-circulating-tumor-cells-in-patients-with-early-and-metastatic-breast-cancer
#1
Eleni Politaki, Sofia Agelaki, Stella Apostolaki, Dora Hatzidaki, Areti Strati, Filippos Koinis, Maria Perraki, Georgia Saloustrou, Giannis Stoupis, Galatea Kallergi, Maria Spiliotaki, Tereza Skaltsi, Evi Lianidou, Vassilis Georgoulias, Dimitrios Mavroudis
BACKGROUND: We directly compared CTC detection rates and prognostic significance, using three different methods in patients with breast cancer (BC). METHODS: Early (n=200) and metastatic (n=164) patients were evaluated before initiating adjuvant or first-line chemotherapy, using the CellSearchTM System, an RT-qPCR for CK-19 mRNA detection and by double immunofluorescence (IF) microscopy using A45-B/B3 and CD45 antibodies. RESULTS: Using the CellSearchTM System, 37% and 16...
November 20, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29161363/improved-survival-in-metastatic-germ-cell-cancer
#2
C D Fankhauser, S Sander, L Roth, J Beyer, T Hermanns
Background: The prognostic score of the International Germ Cell Cancer Collaborative Group (IGCCCG) in metastatic germ-cell cancers (mGCC) relies on treatments delivered before 1990. It is unclear, if this score is still relevant to contemporary cohorts of patients who receive modern-type chemotherapy and supportive care. Patients and Methods: All patients who underwent cisplatin/etoposide based first-line chemotherapy for mGCC at the University Hospital Zurich (USZ) between 1991 and 2016 were identified retrospectively...
November 17, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29158825/noninvasive-imaging-of-cd206-positive-m2-macrophages-as-an-early-biomarker-for-post-chemotherapy-tumor-relapse-and-lymph-node-metastasis
#3
Chenran Zhang, Xinhe Yu, Liquan Gao, Yang Zhao, Jianhao Lai, Dehua Lu, Rui Bao, Bing Jia, Lijun Zhong, Fan Wang, Zhaofei Liu
Tumor relapse after initial regression post-chemotherapy is a major challenge in cancer treatment, as it usually leads to local-regional recurrence or inoperable distant metastasis. M2 macrophages diminish the tumor-inhibitory effect of chemotherapy and correlate with distant metastasis and poor prognosis. In this study, we investigated whether molecular imaging of M2 macrophages could serve as an early biomarker for tumor relapse after chemotherapy and tumor lymph node metastasis in preclinical mouse models...
2017: Theranostics
https://www.readbyqxmd.com/read/29158179/prognostic-factors-affecting-outcomes-in-patients-with-malignant-gi-bleeding-treated-with-a-novel-endoscopically-delivered-hemostatic-powder
#4
Rapat Pittayanon, Rungsun Rerknimitr, Alan Barkun
BACKGROUND AND AIM: Endoscopic hemostatic techniques remain poorly effective for GI tumor bleeding. We assessed Tc-325 (Hemospray) for this indication and determined possible predictors of decreased recurrent bleeding and improved 6-month survival in affected patients. METHODS: This retrospective study identified 99 patients with active malignant GI bleeding (primary or metastatic) treated with Tc-325. Eleven patients were excluded because of incomplete data. Data on patient characteristics and possible predictive factors of early (72-hour) and delayed (7, 14 and 30-day) recurrent bleeding, as well as six-month survival, were collected...
November 17, 2017: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/29158104/impact-of-primary-tumor-location-on-survival-from-eortc-advanced-urothelial-cancer-studies
#5
Marco Moschini, Shahrokh F Shariat, Morgan Rouprêt, Maria De Santis, Joaquim Bellmunt, Cora N Sternberg, Bertrand Tombal, Laurence Collette
OBJECTIVE: The prognostic relevance of primary location of urothelial carcinoma (UC) on survival has been poorly investigated. METHODS: The prospectively collected data from three EORTC advanced UC studies 30924 (M-VAC versus high dose M-VAC), 30986 (MCAVI versus GC arm, among patients unfit for CDDP) and 30987 (GC-Paclitaxel versus GC, among patients fit for CDDP) were used. Patients were grouped by primary tumor location as bladder (BCa) versus upper tract urothelial carcinoma (UTUC)...
November 17, 2017: Journal of Urology
https://www.readbyqxmd.com/read/29158079/bone-metastases-as-the-only-metastatic-site-in-patients-with-urothelial-carcinoma-focus-on-a-special-patient-population
#6
Andrea Necchi, Gregory R Pond, Sumanta K Pal, Neeraj Agarwal, Daniel W Bowles, Elizabeth R Plimack, Evan Y Yu, Sylvain Ladoire, Jack Baniel, Simon Crabb, Gunter Niegisch, Sandy Srinivas, Dominik R Berthold, Jonathan E Rosenberg, Thomas Powles, Aristotelis Bamias, Lauren C Harshman, Joaquim Bellmunt, Matthew D Galsky
BACKGROUND: Patients with exclusive bone metastatic spread from urothelial carcinoma (UC) throughout their disease course represent a rare subgroup with unique clinical features. These patients deserved special consideration in a retrospective multicenter study. PATIENTS AND METHODS: Analyses were made from a pool of 1911 patients with a diagnosis of metastatic UC, from 23 centers. Baseline characteristics, access to treatment, and outcomes were analyzed according to metastatic spread...
November 1, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29157662/evaluation-of-guideline-adherence-in-colorectal-cancer-treatment-in-the-netherlands-a-survey-among-medical-oncologists-by-the-dutch-colorectal-cancer-group
#7
Lotte Keikes, Martijn G H van Oijen, Valery E P P Lemmens, Miriam Koopman, Cornelis J A Punt
BACKGROUND: Clinical guidelines are generated to preserve high-quality evidence-based care. Data on the implementation of guidelines into clinical practice are scarce, despite that guideline adherence prevents over- and undertreatment and correlates with survival. Therefore, we investigated guideline adherence for the systemic treatment in high-risk stage II and stage III colon cancer and metastatic colorectal cancer. PATIENTS AND METHODS: In all Dutch hospitals (n = 88) 1 medical oncologist involved in colorectal cancer care was approached to participate...
November 17, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29157555/-systemic-therapy-for-advanced-endometrial-cancer
#8
REVIEW
Patricia Pautier, Fanny Pommeret
Endometrial cancer has generally a good prognosis when diagnosed at an early stage, but remains incurable at an advanced stage (recurrent or metastatic) with only few therapeutic options. Hormonal therapy is the treatment of choice in case of slow progressive disease with a tumor expressing hormonal receptors due to its favorable safety profile. Taxanes, anthracyclines and platinum compounds are the most active chemotherapy agents with greater response rates when combined, though at the price of a significant toxicity...
November 17, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/29157300/prospects-for-combined-use-of-oncolytic-viruses-and-car-t-cells
#9
REVIEW
Adam Ajina, John Maher
With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic option for cancer patients. In parallel, following the favourable results of several clinical trials, adoptive cell transfer using chimeric antigen receptor (CAR)-redirected T-cells is anticipated to enter routine clinical practice for the management of chemotherapy-refractory B-cell malignancies. However, CAR T-cell therapy for patients with advanced solid tumours has proved far less successful...
November 21, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29157298/impressive-response-to-immunotherapy-in-a-metastatic-gastric-cancer-patient-could-somatic-copy-number-alterations-help-patient-selection
#10
Gustavo Dos Santos Fernandes, Daniel da Motta Girardi, Luiza Dib Batista Bugiato Faria, João Paulo Giacomini Bernardes, Renata de Almeida Coudry
BACKGROUND: Metastatic gastric cancer (GC) is an incurable and aggressive disease with a poor prognosis. Immunotherapy is an attractive approach for treating patients with cancer, and studies using immunotherapy have shown promising results in melanoma, kidney and non-small cell lung cancers, among others. CASE PRESENTATION: We present a case of a 50-year-old woman with metastatic GC whose cancer had progressed after first-line chemotherapy and who received pembrolizumab as an experimental treatment...
November 21, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29157296/biomarkers-for-immunotherapy-in-bladder-cancer-a-moving-target
#11
REVIEW
David H Aggen, Charles G Drake
Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for mUC has seismically shifted following the approval of five therapies targeting the programmed cell death protein (PD-1)/programmed cell death ligand 1 (PD-L1) axis. Notably, the anti-PD-1 antibody pembrolizumab demonstrated improved OS relative to chemotherapy in a randomized phase III study for second line treatment of mUC; this level 1 evidence led to approval from the U...
November 21, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29157085/sequential-occurrence-of-small-cell-and-non-small-lung-cancer-in-a-male-patient-is-it-a-transformation
#12
Ahsan Wahab, Kavitha Kesari, Siddique Chaudhary, Mahin Khan, Hafiz Khan, Susan Smith, Yanis Boumber
Lung cancer is one of the leading causes of cancer-related mortality and is categorized into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). We present a patient with epidermal growth factor receptor (EGFR)-mutant-NSCLC who developed metastatic SCLC after initial therapy with second-generation EGFR-tyrosine kinase inhibitor, afatinib. A 65-year-old male non-smoker was diagnosed with adenocarcinoma of the right lung, stage IVA (M1a). Due to tumor positivity for EGFR-Exon 19 deletion, the patient was started on oral afatinib, which resulted in a partial response...
November 20, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29156913/symptom-clusters-using-the-brief-pain-inventory-in-patients-with-breast-cancer
#13
Vithusha Ganesh, Leah Drost, Nicholas Chiu, Liying Zhang, Leonard Chiu, Ronald Chow, Nicholas Lao, Bo Angela Wan, Justin Lee, Edward Chow, Carlo DeAngelis
BACKGROUND: The purpose of this study was to assess symptom clusters in functional interference using the brief pain inventory (BPI) in patients with non-metastatic breast cancer (BC) during and after chemotherapy. METHODS: A principal component analysis with varimax rotation was conducted on data from 228 patients to identify two clusters at baseline and two intervals following treatment. RESULTS: Physical (general activity, normal work, walking ability) and psychosocial (mood, relationships, sleep, enjoyment of life) interference clusters were present at baseline...
October 18, 2017: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/29156888/chimeric-antigen-receptor-car-t-and-other-t-cell-strategies-for-pancreas-adenocarcinoma
#14
Anna M Varghese
Treatments in metastatic pancreas cancer remain based in cytotoxic chemotherapy, and novel treatment strategies are needed. Building on the emerging role of T cell therapy in hematologic malignancies and our understanding of the underlying biology of pancreas cancer, research is growing in the role of T cell therapy for patients with solid tumors in general and more specifically patients with pancreas cancer. This review will focus on describing the biology of T cell therapy and its current applications in pancreas cancer...
October 24, 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29156447/pd-1-blockade-in-advanced-nsclc-a-focus-on-pembrolizumab
#15
REVIEW
Solange Peters, Keith M Kerr, Rolf Stahel
Non-small cell lung cancer (NSCLC) is one of the most prevalent cancers and is responsible for a large proportion of all cancer-related deaths. Current treatment options are inadequate, reflecting a substantial unmet clinical need. Increasing knowledge regarding the mechanisms and genetic aberrations underlying tumor development and growth has heralded a new era of therapy in oncology, moving away from indiscriminate cytotoxic chemotherapy toward more finely focused, targeted medicine. The development of small-molecule drugs and monoclonal antibodies directed toward specific components of dysfunctional molecular or immune pathways, and mutated genes specific to particular cancer types, is leading the field to more personalized and less toxic treatment options, many of which have demonstrated greater efficacy and survival benefits than their chemotherapeutic counterparts...
October 23, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29155424/immune-checkpoint-inhibitors-in-sarcomas-in-quest-of-predictive-biomarkers
#16
Robin Veenstra, Marie Kostine, Anne-Marie Cleton-Jansen, Noel Fcc de Miranda, Judith Vmg Bovée
Sarcomas are a rare group of tumors of mesenchymal origin. Metastatic sarcomas are often difficult to treat and unresponsive to standard radio- and chemotherapy, resulting in a poor survival rate for patients. Novel treatments with immune checkpoint inhibitors have been proven to prolong survival of patients with a variety of cancers, including metastatic melanoma, lung, and renal cell carcinoma. Since immune checkpoint inhibitors could provide a novel treatment option for patients with sarcomas, clinical trials investigating their efficacy in these group of tumors are ongoing...
November 20, 2017: Laboratory Investigation; a Journal of Technical Methods and Pathology
https://www.readbyqxmd.com/read/29153623/abiraterone-acetate-prednisolone-treatment-beyond-prostate-specific-antigen-and-radiographic-progression-in-metastatic-castration-resistant-prostate-cancer-patients
#17
Krisztina Biró, Barna Budai, Márta Szőnyi, Zsófia Küronya, Fruzsina Gyergyay, Krisztián Nagyiványi, Lajos Géczi
OBJECTIVES: To investigate the overall survival (OS) of chemotherapy refractory patients with metastatic castration-resistant prostate cancer who were treated with abiraterone acetate + prednisolone (AA + P) beyond prostate specific antigen (PSA) and radiographic progression (PRP) until clinical progression in comparison to patients treated until PRP. METHODS: At our institute the AA + P treatment started in 2011 in an early-access protocol trial. In October 2012 AA became generally available...
November 15, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29153431/monoclonal-antibodies-targeting-the-il-17-il-17ra-axis-an-opportunity-to-improve-the-efficiency-of-anti-vegf-therapy-in-fighting-metastatic-colorectal-cancer
#18
REVIEW
Sajida Ibrahim, Alban Girault, Marc Ohresser, Emilie Lereclus, Gilles Paintaud, Thierry Lecomte, William Raoul
Colorectal cancer is a major problem for public health worldwide because of its frequency and its severity. Many efforts have been carried to target the vascular endothelial growth factor (VEGF) pathway, one of the main promoters of pathological angiogenesis. Therapeutic monoclonal antibodies against VEGF have emerged as essential biopharmaceuticals for the advanced stages of the disease, in association with appropriate backbone chemotherapy. Unfortunately, after an initial benefit for the patients, resistance invariably develops...
October 28, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29153430/real-world-effect-of-maintenance-and-intermittent-chemotherapy-on-survival-in-metastatic-colorectal-cancer
#19
Jonathan M Loree, Sean K Tan, Laurence M Lafond, Caroline H Speers, Hagen F Kennecke, Winson Y Cheung
BACKGROUND: With improved survival and longer duration of treatment, clinicians managing metastatic colorectal cancer (mCRC) increasingly consider intermittent (IC) or maintenance chemotherapy (MC), but the effect of these treatment modifications on real-world outcomes is unclear. PATIENTS AND METHODS: Using a population-based cohort of mCRC patients who received combination chemotherapy, we aimed to describe the use of IC/MC and their effect on overall survival (OS)...
October 23, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29151928/serum-pre-albumin-predicts-the-clinical-outcome-in-metastatic-castration-resistant-prostate-cancer-patients-treated-with-abiraterone
#20
Liancheng Fan, Chenfei Chi, Sanwei Guo, Yanqing Wang, Wen Cai, Xiaoguang Shao, Fan Xu, Jiahua Pan, Yinjie Zhu, Xun Shangguan, Zhixiang Xin, Jianian Hu, Hongyang Qian, Shaowei Xie, Rui Wang, Lixin Zhou, Baijun Dong, Wei Xue
Objective To determine the prognostic utility of serum pre-albumin in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (AA). Patients and Methods 112 chemotherapy pretreated or chemotherapy-naive patients were scheduled for systemic treatment with AA. Serum pre-albumin levels were measured before and after 3 months of AA treatment. Univariate and multivariate analyses were performed to determine prognostic factors that were associated with PSA progression-free survival (PSA-PFS), radiographic PFS (rPFS) and overall survival (OS)...
2017: Journal of Cancer
keyword
keyword
40933
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"